

**Electronically Filed**

|   |                      |                      |
|---|----------------------|----------------------|
| <p style="text-align: center;"><b>STATEMENT<br/>CORROBORATING<br/>IDENTITY OF BIOLOGICAL<br/>MATERIAL</b></p> <p>Address to:<br/>Mail Stop<br/>Commissioner for Patents<br/>P.O. Box 1450<br/>Alexandria, VA 22313-1450</p> | Attorney Docket No.  | RICE-032             |
|   | Confirmation No.     | 8992                 |
|   | First Named Inventor | MacKay, Charles Reay |
|   | Application Number   | 10/502,145           |
|   | Filing Date          | 05/05/2005           |
|   | Group Art Unit       | 1644                 |
|   | Examiner Name        | Gambel, Phillip      |
| Title: "Anti-C5ar Antibodies and uses thereof"  |                      |                      |

Sir:

I, Peter Whitfeld, Ph.D., declare:

1. I am the Director of Development & Operations for G2 Inflammation Pty Ltd and G2 Therapies Pty Ltd;
2. I am in a position to corroborate the identity of the biological material being deposited in connection with the above-referenced patent application;
3. Antibody 12D4, which is produced by hybridoma cell line 12D4-N17, has been deposited and accepted under the provisions of the Budapest Treaty at the European Collection of Cell Cultures (ECACC), Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom, and has been assigned accession number 04090801;
4. Antibody 12D4 is a biological material that is specifically identified in the above-referenced patent application;

5. Antibody 12D4 produced by hybridoma cell line 12D4-N17 is identical to the biological material that was originally described in the above-referenced patent application;
6. During the pendency of the above referenced patent application, access to the deposit will be afforded by one determined by the Commissioner to be entitled thereto;
7. All restrictions on the availability to the public of the culture deposited will be irrevocably removed upon the granting of a patent from the above-identified application, however applicants retain the right to require requests for the deposits be made commensurate with 37 CFR §1.808(b);
8. The deposit will be maintained for a period of 30 years after the date of deposit or 5 years after the last request for a sample or for the enforceable life of the patent, whichever is longer;
9. The deposit will be replaced if viable samples cannot be dispensed by the depository;
10. I declare further that all statements made in this Declaration of my own knowledge are true and that all statements made on information and belief are believed to be true and further, that these statements are made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent granted thereon.

Date: 12 April 2011

By: 

Peter Whitfeld, Ph.D  
Director of Development &  
Operations  
G2 Inflammation Pty Ltd and  
G2 Therapies Pty Ltd